Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07170566 · ClinicalTrials.gov registry record
A Retrospective, Observational Study of the Real-world Safety and Performance of InnovaMatrix® AC at a Single Centre
A clinical trial, sponsored by ConvaTec.
- Completed
- Registry status
- 67
- Enrollment target
NCT07170566: Completed study, sponsored by ConvaTec.
NCT07170566 is a clinical trial that has completed, run by ConvaTec. The registered enrollment target is 67 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07170566 has completed, sponsored by ConvaTec.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
Study Summary
The use of a decellularised porcine placental extracellular matrix in hard-to-heal wounds: A retrospective study of the real-world performance of InnovaMatrix® AC at a single centre.
Primary Outcome
Percent area reduction of target wound area at 4 weeks compared to baseline will be listed and tabulated over all eligible subjects, as calculated by wound length multiplied by wound width.
Interventions
- DEVICE innovaMatrix AC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2025-08-05 |
What the finished NCT07170566 record still lists
NCT07170566 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 67 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which innovaMatrix AC is the first listed.
NCT07170566 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07170566 about?
NCT07170566 is a clinical study titled "A Retrospective, Observational Study of the Real-world Safety and Performance of InnovaMatrix® AC at a Single Centre". The use of a decellularised porcine placental extracellular matrix in hard-to-heal wounds: A retrospective study of the real-world performance of InnovaMatrix® AC at a single centre.
What is the current status of trial NCT07170566?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2024-05-01. Estimated completion is 2025-08-05.
What interventions are being tested in trial NCT07170566?
The interventions under investigation include: innovaMatrix AC (DEVICE).
Who is sponsoring clinical trial NCT07170566?
This trial is sponsored by ConvaTec, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI